Open AccessBevacizumab (Avegra®) for the treatment of gynecological cancers: joint experience of several centers
Author(s) -
А. Г. Кедрова,
С. Э. Красильников,
Д С Огай,
Т. А. Максименко,
В. И. Вознесенский,
А. И. Беришвили,
Т. А. Греян
Publication year - 2021
Publication title -
opuholi ženskoj reproduktivnoj sistemy
Language(s) - English
Resource type - Journals
eISSN - 1999-8627
pISSN - 1994-4098
DOI - 10.17650/1994-4098-2020-16-4-84-90
Subject(s) - bevacizumab , medicine , oncology , chemotherapy , vascular endothelial growth factor , drug , vegf receptors , gynecology , surgery , pharmacology
Tumors of the female reproductive system are among the five most common cancers in women worldwide. Up to 60 % of these patients require chemotherapy to reduce the risk of recurrence. Currently, an additional treatment option is available for patients with advanced cancers of the female reproductive system, namely vascular endothelial growth factor inhibitor bevacizumab. To assess the efficacy and safety of Avegra®, Russian generic of bevacizumab, we summarized the experience of 5 specialized healthcare institutions that used it for the treatment of 178 patients with tumors of the female reproductive system. The analysis of side effects in 1,074 treatment cycles demonstrated that Avegra® had a good safety profile. Clinical effects of Avegra® were similar to those of the original drug.